GLP1 Diabetes Showdown Nears As Lyxumia Gets Green Light In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The EU's Committee for Medicinal Products for Human Use has recommended two Sanofi products - the diabetes therapy Lyxumia and the colorectal cancer drug Zaltrap – while also backing the first vaccine in Europe for meningitis B, Novartis' Bexsero.